Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Integra Lifesciences Holdings (IART) Cash & Equivalents (2016 - 2025)

Integra Lifesciences Holdings (IART) has disclosed Cash & Equivalents for 17 consecutive years, with $235.0 million as the latest value for Q4 2025.

  • Quarterly Cash & Equivalents fell 4.6% to $235.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $235.0 million through Dec 2025, down 4.6% year-over-year, with the annual reading at $235.0 million for FY2025, 4.6% down from the prior year.
  • Cash & Equivalents hit $235.0 million in Q4 2025 for Integra Lifesciences Holdings, up from $232.2 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $591.9 million in Q1 2024 to a low of $215.2 million in Q2 2024.
  • Historically, Cash & Equivalents has averaged $348.6 million across 5 years, with a median of $308.3 million in 2023.
  • Biggest five-year swings in Cash & Equivalents: skyrocketed 92.57% in 2024 and later crashed 59.6% in 2025.
  • Year by year, Cash & Equivalents stood at $513.4 million in 2021, then decreased by 11.06% to $456.7 million in 2022, then tumbled by 39.47% to $276.4 million in 2023, then dropped by 10.86% to $246.4 million in 2024, then decreased by 4.6% to $235.0 million in 2025.
  • Business Quant data shows Cash & Equivalents for IART at $235.0 million in Q4 2025, $232.2 million in Q3 2025, and $217.9 million in Q2 2025.